007370 — Jin Yang Pharmaceutical Co Balance Sheet
0.000.00%
- KR₩60bn
- KR₩57bn
- KR₩94bn
- 89
- 88
- 12
- 73
Annual balance sheet for Jin Yang Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 5,456 | 5,325 | 14,875 | 10,494 | 8,595 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 15,809 | 15,441 | 17,012 | 20,248 | 21,788 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 28,082 | 28,712 | 41,005 | 46,329 | 48,029 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 28,505 | 27,761 | 39,363 | 43,794 | 44,136 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 68,278 | 71,591 | 98,502 | 114,444 | 119,907 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 19,926 | 18,507 | 27,143 | 30,938 | 24,511 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 24,612 | 23,320 | 33,184 | 36,869 | 30,323 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 43,666 | 48,270 | 65,318 | 77,575 | 89,583 |
Total Liabilities & Shareholders' Equity | 68,278 | 71,591 | 98,502 | 114,444 | 119,907 |
Total Common Shares Outstanding |